Concept: A randomised multicentre trial of first line chemotherapy comparing three weekly cabazitaxel versus weekly paclitaxel in HER2 negative metastatic breast cancerAmit Bahl, Mark Churn, Sidharth Dubey et al.|The Breast|2022Cited by 7
Randomized multicenter trial of 3 weekly cabazitaxel versus weekly paclitaxel chemotherapy in the first-line treatment of HER2 negative metastatic breast cancer (MBC).Amit Bahl, William Wilson, Jeremy Braybrooke et al.|Journal of Clinical Oncology|2021Cited by 2